Singaravelu Jagadeesan, MD
Neurology · Gastonia, NCNPI 1053418509
Payments from drug & device makers
Across 225 payments — averaging $5148.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$574K
- Eli Lilly$183K
- UCB SA$109K
- Vanda Pharmaceuticals Inc.$85K
- Teva Pharmaceuticals USA, Inc.$38K
- Biohaven Pharmaceutical Holding Company Ltd.$32K
- plus $136K from 18 others
Across 4 payments — averaging $1373.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
- Pfizer$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $574,096 |
| Eli Lilly | 4 | $183,391 |
| UCB SA | 1 | $109,033 |
| Vanda Pharmaceuticals Inc. | 9 | $85,450 |
| Teva Pharmaceuticals USA, Inc. | 21 | $38,028 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $32,484 |
| Pfizer | 6 | $29,432 |
| Genentech, Inc. | 9 | $24,352 |
| Novartis | 1 | $20,978 |
| Jazz Pharmaceuticals Inc. | 50 | $19,270 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $16,382 |
| Sage Therapeutics, LLC | 5 | $13,368 |
| Acadia Pharmaceuticals Inc | 2 | $8,200 |
| Eisai Inc. | 2 | $2,923 |
| Axsome Therapeutics, Inc. | 15 | $567 |
| Biogen | 1 | $150 |
| W. L. Gore & Associates, Inc. | 1 | $120 |
| Arbor Pharmaceuticals, Inc. | 4 | $49 |
| SK Life Science, Inc. | 1 | $47 |
| Merck | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Resmed Corp | 1 | $20 |
| Protega Pharmaceutials Inc | 1 | $19 |
| Harmony Biosciences LLC | 1 | $16 |
How this compares
$1,158,428 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Gastonia
- Mohammad BolouriCharlotte$16.6M
- Katherine PetersDurham$11M
- John ScagnelliRaleigh$9.3M
- T RaoCharlotte$4M
- Pramod SethiGreensboro$2.9M
- Robert ArmstrongAsheville$2.7M
- Casey JeffreysRaleigh$2.2M
- Mitchell IsaacWinston Salem$2.2M
- Vern JuelDurham$2M
- Marshall FreemanGreensboro$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.